RaQualia Pharma (TSE:4579) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
54 GF Score
Price 円453.00
GF Value 円310.66
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSE:4579
54GF Score
RaQualia Pharma Inc TSE:4579
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円453.00 is trading 45.8% above its estimated GF Value™ of 円310.66. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Dividends Received:
  • GF Value™: 円310.66 vs. price of 円453.00 (45.8% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
54GF Score

Get the complete analysis for TSE:4579

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円453.00
Price
円310.66
GF Value